Bristol Myers Squibb (BMY) Accounts Payables (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Accounts Payables for 18 consecutive years, with $4.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables fell 23.38% year-over-year to $4.2 billion in Q2 2026; TTM through Jun 2026 was $4.2 billion, a 23.38% decrease from a year earlier, with the FY2025 full-year figure at $3.6 billion, down 0.75% from the prior year.
• Accounts Payables was $4.2 billion for Q2 2026 at Bristol Myers Squibb, down from $4.2 billion in the prior quarter.
• Over five years, Accounts Payables peaked at $5.4 billion in Q2 2025 and troughed at $2.6 billion in Q3 2022.
• A 5-year average of $3.5 billion and a median of $3.5 billion in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 44.68% in 2025 and retreated 23.38% in 2026, its largest moves.
• Over 5 years, Accounts Payables stood at $3.0 billion in 2022, then rose by 7.2% to $3.3 billion in 2023, then advanced by 10.52% to $3.6 billion in 2024, then retreated by 0.75% to $3.6 billion in 2025, then advanced by 16.31% to $4.2 billion in 2026.
• The last three Accounts Payables figures came in at $4.2 billion (Q2 2026), $4.2 billion (Q1 2026), and $3.6 billion (Q4 2025), per Business Quant data.